Hideaki Katori
Overview
Explore the profile of Hideaki Katori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, et al.
Int J Clin Oncol
. 2009 Aug;
14(4):337-43.
PMID: 19705245
Background: Chemotherapy-induced nausea and vomiting (CINV) remains a significant problem for patients and is associated with a substantial deterioration in quality of life; appropriate use of antiemetic drugs is crucial...
2.
Katori H, Nozawa A, Tsukuda M
Acta Otolaryngol
. 2007 Sep;
127(11):1207-13.
PMID: 17851915
Conclusion: Quantitative assessment is more sensitive as a measure of cellular protein content as compared with standard optical density measurements. The data support the hypothesis that increased epidermal growth factor...
3.
Katori H, Tsukuda M, Taguchi T
Acta Otolaryngol
. 2007 Sep;
127(10):1099-104.
PMID: 17851890
Conclusions: Concurrent chemoradiotherapy with carboplatin and uracil-f tegafur (UFT) seems to be a promising and appropriate regimen for patients with poor performance status (PS) with locally advanced squamous cell carcinoma...
4.
Katori H, Nozawa A, Tsukuda M
Acta Otolaryngol
. 2007 Apr;
127(5):540-6.
PMID: 17453482
Conclusion: Increasing cell proliferation seems to be a very important factor in the development of inverted papilloma (IP). Apoptosis that was increased but weakly inhibited by Bcl-2 did not cause...
5.
Katori H, Tsukuda M
Acta Otolaryngol
. 2006 Nov;
126(12):1309-14.
PMID: 17101593
Conclusion: This concurrent chemoradiotherapy with CPA, THP, and CDDP showed major antitumor activity with manageable toxicity as treatment of advanced salivary gland carcinoma patients. The high response rate (RR) justifies...
6.
Katori H, Tsukuda M, Watai K
Cancer Chemother Pharmacol
. 2006 Nov;
60(3):399-406.
PMID: 17096160
Purpose: Radiotherapy (RTx) has been considered as the treatment for locally advanced squamous cell carcinoma of the head and neck (SCCHN). However, with only conventional fractionation (Cfx), response rates are...
7.
Katori H, Tsukuda M, Taguchi T
Cancer Chemother Pharmacol
. 2006 Oct;
59(6):789-94.
PMID: 17053926
Purpose: The aim of this study was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy using cisplatin (CDDP), 5-fluorouracil (5-FU), methotrexate (MTX) and leucovorin (LV) (PFML) in patients with...
8.
Katori H, Nozawa A, Tsukuda M
Auris Nasus Larynx
. 2006 Oct;
34(1):79-84.
PMID: 17049779
Objectives: In the present study, we attempted to identify cyclooxygenase-2 (COX-2) expression and Ki-67 index in carcinoma ex-pleomorphic adenoma (Ca ex-PA) using quantitative immunohistochemical analysis and to compare the benign...
9.
Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, et al.
Gan To Kagaku Ryoho
. 2006 Aug;
33 Suppl 1:172-8.
PMID: 16897997
Most cases of head and neck squamous cell carcinoma (HNSCC) are in the advanced stages, resulting in a poor prognosis. To improve the poor outcome, adjuvant chemotherapy is indispensable for...
10.
Tsukuda M, Ishitoya J, Mikami Y, Matsuda H, Katori H, Horiuchi C, et al.
Gan To Kagaku Ryoho
. 2006 Aug;
33 Suppl 1:144-9.
PMID: 16897991
Most head and neck carcinomas are squamous cell carcinomas (HNSCCs). The combination of cisplatin with a continuous infusion of 5-fluorouracil (5-FU) has been a standard chemotherapy regimen for HNSCC. Based...